Consilium Smartphone App for Real-World Electronically Captured Patient-Reported Outcome Monitoring in Cancer Patients Undergoing anti-PD-L1-Directed Treatment
Open Access
- 1 January 2020
- journal article
- research article
- Published by S. Karger AG in Case Reports in Oncology
- Vol. 13 (2), 491-496
- https://doi.org/10.1159/000507345
Abstract
Digital patient monitoring gains importance for quality of clinical cancer care. Our case report provides insight into usability and acceptance of a smartphone app for monitoring of electronically captured patient-reported outcomes in patients undergoing immunotherapy. During 3 months, 6 patients with advanced or metastatic PD-L1-positive cancer of the lung, prostate, and bladder who underwent checkpoint immunotherapy were using the Consilium app for standardized and structured electronic reporting of symptoms and therapy side effects. We evaluated the number and quality of symptom entries as well as usability and safety of shared reporting between the patient and the treating physician. Duration of anti-PD-L1-directed immunotherapy in the 6 patients ranged from 4 to 10 months and comprised a total of 21 anti-PD-L1-directed immunotherapy cycles. Patients reported between 4 and 16 different symptoms, of which the most frequent (57%) were dry cough, fatigue, shortness of breath, fever, and appetite loss. Overall, 1,279 symptom entries were counted, corresponding to 2.4 symptom entries per patient per day. Symptom severity grading ranged from 0.1 (very slight symptoms) to 7.8 (severe symptoms), which triggered prespecified alerts in 4 of the 6 patients. No unplanned visits were noted, and no safety issues occurred. Satisfaction with the app usability was high, as was the beneficial effect on consultation. Usability and reviewed data entries indicate high shared reporting efforts of patients and treating physicians and overall satisfaction with electronically reported patient outcomes.This publication has 8 references indexed in Scilit:
- Patient-reported outcomes from the randomized phase III ALEX study of alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancerLung Cancer, 2019
- Reporting Standards for Patient-Reported Outcomes in Clinical Trial Protocols and PublicationsJNCI Journal of the National Cancer Institute, 2019
- ePROs in the follow-up of cancer patients treated with immune checkpoint inhibitors: a retrospective studyZeitschrift für Krebsforschung und Klinische Onkologie, 2019
- High Compliance Rates With Patient-Reported Outcomes in Oncology Trials Submitted to the US Food and Drug AdministrationJNCI Journal of the National Cancer Institute, 2018
- Making a picture worth a thousand numbers: recommendations for graphically displaying patient-reported outcomes dataQuality of Life Research, 2018
- A Mobile App to Stabilize Daily Functional Activity of Breast Cancer Patients in Collaboration With the Physician: A Randomized Controlled Clinical TrialJournal of Medical Internet Research, 2016
- Patient-reported outcome measurement in drug discovery: a tool to improve accuracy and completeness of efficacy and safety dataExpert Opinion on Drug Discovery, 2016
- Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled TrialJournal of Clinical Oncology, 2016